Innogen (02591.HK): Proposes On‑Market H‑Share Buy‑back of Approximately HK$50 Million

NewTimeSpace News: On August 26, 2026, Innogen (02591.HK) announced that the Board proposes to repurchase H‑shares by way of on‑market transactions on the Main Board of HKEX under the buy‑back authority, commencing on 26 August 2026 and ending on the date of the next Annual General Meeting, with an intended total consideration of approximately HK$50 million. Repurchased H‑shares will be held as treasury shares, intended for the Company’s share‑incentive scheme and/or for direct cancellation in accordance with applicable laws.

Yinno Pharma stated that a special resolution was passed at the Annual General Meeting on 29 June 2026 granting the Board general authority to repurchase up to 10% of the total issued H‑shares. The buy‑back will be funded by the Company’s internal resources while maintaining sound financial position.

NewTimeSpace Disclaimer: All content herein is the original work of NewTimeSpace. Any reproduction, reprinting, or use of this content in any other manner must clearly indicate the source as "NewTimeSpace". NewTimeSpace and its authorized third-party information providers strive to ensure the accuracy and reliability of the data, but do not guarantee the absolute correctness thereof. This content is for reference only and does not constitute any investment advice. All transaction risks shall be borne by the user.